Citadel Advisors
TSHA icon

Citadel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Citadel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
1,535,287
+1,124,152
+273% +$6.65M ﹤0.01% 3503
2026
Q1 		$1.84M Sell
411,135
-1,443,720
-78% -$6.71M ﹤0.01% 6255
2025
Q4 		$10.2M Buy
1,854,855
+1,487,546
+405% +$7.22M ﹤0.01% 3235
2025
Q3 		$1.2M Sell
367,309
-161,684
-31% -$458K ﹤0.01% 7144
2025
Q2 		$1.22M Buy
528,993
+312,382
+144% +$679K ﹤0.01% 6660
2025
Q1 		$301K Sell
216,611
-528,594
-71% -$884K ﹤0.01% 9580
2024
Q4 		$1.29M Sell
745,205
-2,114,767
-74% -$4.39M ﹤0.01% 6519
2024
Q3 		$5.75M Buy
2,859,972
+2,813,118
+6,004% +$6.17M ﹤0.01% 3736
2024
Q2 		$105K Buy
46,854
+46,657
+23,684% +$136K ﹤0.01% 10845
2024
Q1 		$566 Sell
197
-2,297,359
-100% -$4.79M ﹤0.01% 14308
2023
Q4 		$4.07M Buy
+2,297,556
New +$4.58M ﹤0.01% 4099
2023
Q3 		– Sell
-11,293
Closed -$21.1K – 15133
2023
Q2 		$7.46K Hold
11,293
– – ﹤0.01% 13371
2023
Q1 		$9.01K Sell
11,293
-172,418
-94% -$223K ﹤0.01% 13613
2022
Q4 		$415K Buy
183,711
+133,131
+263% +$270K ﹤0.01% 8628
2022
Q3 		$97K Sell
50,580
-60,011
-54% -$218K ﹤0.01% 11123
2022
Q2 		$411K Sell
110,591
-98,158
-47% -$389K ﹤0.01% 9092
2022
Q1 		$1.36M Buy
208,749
+172,412
+474% +$1.29M ﹤0.01% 6950
2021
Q4 		$423K Buy
+36,337
New +$548K ﹤0.01% 10075
2021
Q1 		– Sell
-35,752
Closed -$949K – 13725
2020
Q4 		$949K Sell
35,752
-209,282
-85% -$4.51M ﹤0.01% 6904
2020
Q3 		$5.49M Buy
+245,034
New +$5.76M ﹤0.01% 3015

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's TSHA Position: Q2 2026 in Review

Citadel Advisors increased its Taysha Gene Therapies (TSHA) stake by 273% in Q2 2026, buying an estimated $6.65M and bringing the position to 1,535,287 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

Citadel Advisors first reported a position in TSHA in Q3 2020 and has held it in 20 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Citadel Advisors held 1,535,287 shares of Taysha Gene Therapies worth $10.5M as of Q2 2026.
  • Citadel Advisors bought 1,124,152 Taysha Gene Therapies shares in Q2 2026, an estimated $6.65M.
  • Taysha Gene Therapies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3503 holding.
  • Citadel Advisors first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 20 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.